DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitor is a new class of anti-diabetic drug which exerts its glucose-lowering action by suppressing the degradation of a gut incretin hormone glucagon-like peptide-1 (GLP-1). To elucidate whether treatment with stronger DPP-4 inhibitor on top of angiotensin II type 1 receptor blocker (ARB) provides greater renal protective effects, we performed a crossover study with two DPP-4 inhibitors, sitagliptin and alogliptin, in twelve type 2 diabetic patients with incipient nephropathy taking ARBs. This study consisted of three treatment periods: sitagliptin 50 mg/day for 4 weeks (first period), alogliptin 25 mg/day for 4 weeks (second period), and sitagliptin 50 mg/day for 4 weeks (third period). Significant changes in body mass index, blood pressure, serum lipids, serum creatinine, estimated glomerular filtration rate, and HbA1c were not observed among the three treatment periods. Reduced urinary levels of albumin and an oxidative stress marker 8-hydroxy-2'-deoxyguanosine (8-OHdG), increased urinary cAMP levels, and elevated plasma levels of stromal cell-derived factor-1α (SDF-1α) which is a physiological substrate of DPP-4 were observed after the switch from sitagliptin to a stronger DPP-4 inhibitor alogliptin. Given a large body of evidence indicating anti-oxidative action of cAMP and up-regulation of cellular cAMP production by SDF-1α, the present results suggest that more powerful DPP-4 inhibition on top of angiotensin II type 1 receptor blockade would offer additional protection against early-stage diabetic nephropathy beyond that attributed to glycemic control, via reduction of renal oxidative stress by SDF-1α-cAMP pathway activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 14×
“In the present study, we could not measure plasma active GLP-1 levels.”
BackgroundInfluentialBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“cAMP is an important second messenger on various signal transduction pathways, and also works as the primary effector of GLP-1-induced insulin secretion from pancreatic β-cells [21-23].”
BackgroundOxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0039 · Cited by 2,232
Lazarini, F., Tham, T. N., Casanova, P., Arenzana‐Seisdedos, F., & Dubois‐Dalcq, M. (2003) · Glia · doi:10.1002/glia.10139 · Cited by 280
Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., & for the INNOVATION Study Group (2007) · Diabetes Care · doi:10.2337/dc06-1998 · Cited by 230
Ghosh, S., Khazaei, M., Moien-Afshari, F., Ang, L. S., Granville, D. J., Verchere, C. B., Dunn, S. R., McCue, P., Mizisin, A., Sharma, K., et al. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90548.2008 · Cited by 113
Leech, C. A., Chepurny, O. G., & Holz, G. G. (2010) · Vitamins & Hormones · doi:10.1016/b978-0-12-381517-0.00010-2 · Cited by 76
Cited by
Diabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Therapeutic approaches to diabetic nephropathy—beyond the RAS
Fernandez-Fernandez, B., Ortiz, A., Gomez-Guerrero, C., & Egido, J. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.74 · Cited by 170
“73 m2, UACR ≥200 mg/g, on RAS blockade (58) Not available”
BackgroundDiabetic nephropathy: Time to withhold development and progression - A review
Sharaf El Din, U. A. A., Salem, M. M., & Abdulazim, D. O. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.004 · Cited by 53
“Reduced UAE was observed after the switch from sitagliptin to alogliptin [59].”
Background
Metadata
- Authors
- Fujita, H., Taniai, H., Murayama, H., Ohshiro, H., Hayashi, H., Sato, S., Kikuchi, N., Komatsu, T., Komatsu, K., Komatsu, K., Narita, T., & Yamada, Y.
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2014
- Volume
- 61
- Issue
- 2
- Pages
- 159-166
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- OpenAlex
- W2080648967
- Cited by
- 88
- References
- 7
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.